Special Issue

Pharmacotherapy of Dyslipidemias, 2nd Edition

Message from the Guest Editors

Dyslipidemia is a clinical condition characterized by changes in plasma lipoprotein concentrations in relation to reference values considered as normal. The increase in the concentration of blood circulating lipids induces an inflammatory process that leads to endothelial damage and then the formation of atherosclerosis plaques, an important cardiovascular risk factor responsible for complications such as acute myocardial infarction and stroke. Such lesions can be prevented or reduced by the action of antioxidant phytochemicals present in fruits and vegetables, which have been shown to be a promising alternative to the adverse effects associated with the use of classic lipid-lowering drugs. such as myalgia and the elevation of hepatic transaminases induced using statins. This Special Issue focuses on non-clinical and clinical studies that report advances in the pharmacological therapy of dyslipidemias and associated disorders, such as cardiovascular diseases. Original and review articles as well as case reports concerning classical treatments to novel promising compounds synthetically obtained or from natural sources are welcomed.

Guest Editors

Dr. Daniel Dias Rufino Arcanio

LAFMOL–Laboratory of Functional and Molecular Studies in Physiopharmacology, Department of Biophysics and Physiology, Federal University of Piauí, Teresina 64049-550, Brazil

Dr. Maria do Carmo de Carvalho e Martins

Department of Biophysics and Physiology, Federal University of Piauí, Teresina 64049-550, Brazil

Deadline for manuscript submissions

29 May 2026



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/221335

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

